enVista Envy hydrophobic acrylic intraocular lens (IOL), enVista Envy toric hydrophobic acrylic intraocular lens (IOL)
Bausch + Lomb, Inc. · Decision date Oct 10, 2024
What did the FDA approve?
FDA records P240005 as an original PMA application. The recorded decision is approval, dated Oct 10, 2024.
FDA approval order statement
Approval for the enVista Envy hydrophobic acrylic intraocular lens (IOL) and the enVista Envy toric hydrophobic acrylic IOL. The enVista Envy hydrophobic acrylic IOL (non-preloaded model: EN / preloaded into shuttle model: EPN) is indicated for primary implantation in the capsular bag of the eye in adult patients for the visual correction of aphakia with less than or equal to 1.0 D preoperative corneal astigmatism following removal of a cataractous lens to mitigate the effects of presbyopia by providing improved intermediate and near visual acuity, while maintaining comparable distance visual acuity to an aspheric monofocal IOL. The enVista Envy Toric hydrophobic acrylic IOL (non-preloaded model: ETN / preloaded into shuttle model: ETPN) is indicated for primary implantation in the capsular bag of the eye in adult patients for the visual correction of aphakia and corneal astigmatism following removal of a cataractous lens to mitigate the effects of presbyopia by providing improved intermediate and near visual acuity, while maintaining comparable distance visual acuity to an aspheric monofocal IOL.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Ophthalmic
- Decision date
- Oct 10, 2024
Regulatory record facts
- Identifier
- P240005
- Regulatory pathway
- Premarket approval application
- Applicant
- Bausch + Lomb, Inc.
- Product code
- MFK
- Decision code
- APPR
- Decision date
- Oct 10, 2024
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Lens, multifocal intraocular.
- Applicant
- Bausch + Lomb, Inc.
- Product code
- MFK
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P240005 received
Application receipt date recorded by FDA.
P240005 · FDA decision
APPR
P240005/S007 · Related supplement
enVista Envy hydrophobic acrylic intraocular lens (IOL)
P240005/S008 · Related supplement
enVista Envy Hydrophobic Acrylic Intraocular Lens
P240005/S009 · Related supplement
enVista Envy Hydrophobic Acrylic Intraocular Lens
P240005/S010 · Related supplement
enVista Envy Hydrophobic Acrylic Intraocular Lens
Timeline entries are records held by MedtechLedger for P240005. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P240005
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Bausch + Lomb, Inc. | PMA supplement | Sep 3, 2026 | FDA | |
| Bausch + Lomb, Inc. | PMA supplement | Sep 30, 2026 | FDA | |
| Bausch + Lomb, Inc. | PMA supplement | Oct 14, 2026 | FDA | |
| Bausch + Lomb, Inc. | PMA supplement | Oct 23, 2026 | FDA |
Explore the linked device profile
Other records with product code MFK
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
ClearView HD intraocular lens (IOL)P200020/S013 | Lenstec, Inc. | PMA supplement | Oct 23, 2026 | FDA |
TECNIS Multi-focal 3-pc, Model ZMA00P080010/S032 | Johnson & Johnson Surgical Vision, Inc. | PMA supplement | Oct 19, 2026 | FDA |
| Rayner Intraocular Lenses , Ltd. | PMA supplement | Sep 24, 2026 | FDA | |
| Lenstec, Inc. | PMA approval | Jul 22, 2022 | FDA | |
| Johnson & Johnson Surgical Vision, Inc. | PMA approval | Jan 16, 2009 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Bausch + Lomb, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 1400 N. Goodman St., Rochester, NY, 14609
Sources and methodology
- Original FDA record: P240005
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



